百花医药
(600721)
| 流通市值：30.12亿 | | | 总市值：30.12亿 |
| 流通股本：3.84亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 67,613,090.24 | 272,048,128.25 | 105,220,486.73 | 161,732,145.76 |
| 应收票据及应收账款 | 112,049,691.64 | 84,796,881.78 | 31,763,489.09 | 34,252,337.74 |
| 其中：应收票据 | 6,330,152.91 | 3,832,188.91 | 565,120.44 | 543,710 |
| 应收账款 | 105,719,538.73 | 80,964,692.87 | 31,198,368.65 | 33,708,627.74 |
| 应收款项融资 | 5,834,378.32 | 5,934,432.39 | 6,967,470.03 | 3,106,123.32 |
| 预付款项 | 7,391,206.93 | 3,017,390.57 | 8,656,140.84 | 8,908,166.51 |
| 其他应收款合计 | 4,686,947.89 | 3,700,344.67 | 5,665,810.65 | 4,228,499.94 |
| 存货 | 104,429,899.38 | 99,723,149.71 | 121,358,177.12 | 126,870,992.29 |
| 合同资产 | 99,429,233.77 | 111,303,976.88 | 183,771,871.95 | 176,212,299.09 |
| 其他流动资产 | 2,732,747.91 | 2,747,572.44 | 11,973,956.65 | 11,667,985.56 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 582,017,196.08 | 583,271,876.69 | 617,357,403.06 | 602,258,550.21 |
| 非流动资产: | | | | |
| 长期股权投资 | 59,904,214.67 | 59,910,943.3 | 59,931,304.77 | 59,790,754.89 |
| 其他权益工具投资 | 3,861,309.55 | 3,861,309.55 | 3,959,959.1 | 3,959,959.1 |
| 投资性房地产 | 245,250,300 | 245,250,300 | 245,375,300 | 245,375,300 |
| 固定资产 | 141,218,081.72 | 140,026,004.25 | 141,259,184.16 | 145,127,725.8 |
| 使用权资产 | 31,638.45 | 79,096.11 | 439,311.8 | 482,965.01 |
| 无形资产 | 7,957,887.26 | 8,413,998.95 | 8,898,610.62 | 9,383,222.31 |
| 开发支出 | 31,481,083.12 | 27,482,385.83 | 21,187,445.72 | 16,958,969.16 |
| 商誉 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 |
| 长期待摊费用 | 2,418,079.6 | 2,705,109.19 | 2,718,983.28 | 2,520,648.16 |
| 递延所得税资产 | 31,785,866.31 | 31,776,278.38 | 14,512,040.61 | 14,504,937.08 |
| 其他非流动资产 | 3,863,755.23 | 281,716.26 | 154,592.92 | 524,361.06 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 539,257,293.55 | 531,272,219.46 | 509,921,810.62 | 510,113,920.21 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,121,274,489.63 | 1,114,544,096.15 | 1,127,279,213.68 | 1,112,372,470.42 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 91,208,448.98 | 86,651,748.4 | 114,618,131.37 | 112,134,876.56 |
| 应付账款 | 91,208,448.98 | 86,651,748.4 | 114,618,131.37 | 112,134,876.56 |
| 合同负债 | 134,795,954.56 | 140,505,029.12 | 137,193,752.77 | 131,584,085.02 |
| 应付职工薪酬 | 15,594,033.62 | 27,347,408.03 | 24,518,354.55 | 21,264,999.7 |
| 应交税费 | 3,383,838.75 | 4,070,131.29 | 3,116,872.25 | 3,180,606.24 |
| 其他应付款合计 | 39,715,803.81 | 40,783,796.36 | 53,514,982.95 | 57,548,213.99 |
| 应付股利 | 121,146.5 | 121,146.5 | 121,146.5 | 121,146.5 |
| 一年内到期的非流动负债 | 38,770.93 | 96,927.31 | 176,799.44 | 174,676.99 |
| 其他流动负债 | 9,369,419.94 | 9,666,042.49 | 7,082,678.29 | 6,766,792.41 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 294,106,270.59 | 309,121,083 | 340,221,571.62 | 332,654,250.91 |
| 非流动负债: | | | | |
| 租赁负债 | - | - | 236,469.64 | 374,776.43 |
| 长期应付职工薪酬 | 1,160,336.76 | 1,163,724.45 | 726,933.95 | 733,221.68 |
| 预计负债 | 1,097,589.71 | 1,097,589.71 | 1,097,589.71 | 1,097,589.71 |
| 递延收益 | 1,014,215.25 | 1,059,965.25 | 1,455,558.39 | 1,566,919.12 |
| 递延所得税负债 | 44,037,233.09 | 43,520,015.45 | 43,522,221.58 | 42,995,427.18 |
| 其他非流动负债 | - | - | 0 | - |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 47,309,374.81 | 46,841,294.86 | 47,038,773.27 | 46,767,934.12 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 341,415,645.4 | 355,962,377.86 | 387,260,344.89 | 379,422,185.03 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 384,144,335 | 384,032,635 | 383,123,080 | 381,993,270 |
| 资本公积 | 2,266,275,969.37 | 2,265,831,403.37 | 2,265,605,258.16 | 2,260,958,743.34 |
| 其他综合收益 | 7,195,146.14 | 7,195,146.14 | 7,293,795.69 | 7,293,795.69 |
| 盈余公积 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 |
| 未分配利润 | -1,882,786,880.69 | -1,903,507,740.63 | -1,921,033,539.47 | -1,922,325,798.05 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 779,858,844.23 | 758,581,718.29 | 740,018,868.79 | 732,950,285.39 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 779,858,844.23 | 758,581,718.29 | 740,018,868.79 | 732,950,285.39 |
| 负债和股东权益合计 | 1,121,274,489.63 | 1,114,544,096.15 | 1,127,279,213.68 | 1,112,372,470.42 |
| 公告日期 | 2025-04-26 | 2025-03-12 | 2024-10-25 | 2024-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |